A. Wang-Gillam
Immunology · 2012–2016
A researcher in the Science corpus: 6 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 39 citations into it
- Molecular Biology — 22 citations into it
Whom A. Wang-Gillam trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Pollard (in Immunology)
Papers from A. Wang-Gillam's perspective
Ordered by how strongly the researchers A. Wang-Gillam trusts endorse each paper. Same corpus, a different order for every researcher.
- Hallmarks of cancer: the next generation. (Cell)
- Immunity, Inflammation, and Cancer (Cell)
- CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis (Nature)
- Trophic macrophages in development and disease (Nature reviews. Immunology)
- Alternative activation of macrophages: an immunologic functional perspective. (Annual Review of Immunology)
- Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. (Cancer Research)
- Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia (Cancer Cell)
- Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer (Cancer Cell)
- IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. (Genes & Development)
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. (2016) — 980 citations
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016) — 787 citations
- Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy (2016) — 910 citations
- Phase 1b study targeting tumour associated macrophages with CCR2 inhibition plus FOLFIRINOX in locally advanced and borderline resectable pancreatic cancer (2016) — 664 citations
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T Cell Checkpoint Immunotherapy in Pancreatic Cancer Models (2014) — 1,178 citations
- Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression and improves chemotherapeutic responses (2012) — 902 citations